Clinical Research Directory
Browse clinical research sites, groups, and studies.
MetSense Pilot and Feasibility
Sponsor: Kaiser Permanente
Summary
People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.
Official title: Optimizing Care to Prevent Diabetes and Promote Cardiovascular Health Among Younger Adults With Severe Mental Illness
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20000
Start Date
2025-12-01
Completion Date
2026-12-31
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
MetSense Risk Flag
The MetSense risk flag alerts the clinician if the patient has high diabetes risk and prompts additional diabetes risk management.
Usual Care
Participants will receive usual care.
Locations (1)
KPNC Division of Research
Pleasanton, California, United States